Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations
- Conditions
- Secondary Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaTherapy-Related Acute Myeloid Leukemia
- Interventions
- Drug: PacritinibDrug: CytarabineDrug: DecitabineOther: Laboratory Biomarker AnalysisDrug: Daunorubicin HydrochlorideOther: Pharmacological Study
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Bhavana Bhatnagar
- Target Recruit Count
- 13
- Registration Number
- NCT02323607
- Locations
- 🇺🇸
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 289
- Registration Number
- NCT02319135
- Locations
- 🇪🇸
Hospital Universitari i Politècnic La Fe, Valencia, Spain
A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- Conditions
- Acute Myeloid LeukemiaFLT3-mutated Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 97
- Registration Number
- NCT02310321
- Locations
- 🇯🇵
Site JP81037, Anjo, Aichi, Japan
🇯🇵Site JP00003, Nagoya, Aichi, Japan
🇯🇵Site JP81003, Nagoya, Aichi, Japan
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2019-05-17
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 91
- Registration Number
- NCT02306291
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT02305563
- Locations
- 🇺🇸
Ucla Center Health Sci, Los Angeles, California, United States
🇧🇷Fundacao Pio Xii Hosp Cancer De Barretos, Barretos, Sao Paulo, Brazil
🇧🇷Liga Paranaense De Combate Ao Cancer Erasto Gaertner, Curitiba, Parana, Brazil
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Interventions
- Drug: CarfilzomibDrug: DexamethasoneDrug: MitoxantroneDrug: PEG-asparaginaseDrug: VincristineDrug: Intrathecal (IT) MethotrexateDrug: Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)Drug: 6-MercaptopurineDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT02303821
- Locations
- 🇺🇸
Childrens Healthcare of Atlanta, Egleston, Atlanta, Georgia, United States
🇺🇸West Virginia University Medicine Childrens, Morgantown, West Virginia, United States
🇹🇷Medical Park Bahcelievler Hastanesi, Istanbul, Turkey
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Interventions
- Drug: mitoxantrone hydrochlorideDrug: selinexorDrug: etoposideDrug: cytarabineOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Alice Mims
- Target Recruit Count
- 23
- Registration Number
- NCT02299518
- Locations
- 🇺🇸
The State Ohio University Comprehensive Cancer Center, Columbus, Ohio, United States
Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma
- Conditions
- Contiguous Stage II Adult Lymphoblastic LymphomaStage IV Adult Lymphoblastic LymphomaStage III Adult Lymphoblastic LymphomaNoncontiguous Stage II Adult Lymphoblastic LymphomaStage I Adult Lymphoblastic LymphomaUntreated Adult Acute Lymphoblastic Leukemia
- Interventions
- Drug: carfilzomibDrug: cyclophosphamideDrug: vincristine sulfateDrug: doxorubicin hydrochlorideDrug: dexamethasoneDrug: methotrexateDrug: cytarabineDrug: leucovorin calciumDrug: methylprednisoloneBiological: rituximabOther: laboratory biomarker analysis
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Mehrdad Abedi, MD
- Target Recruit Count
- 10
- Registration Number
- NCT02293109
- Locations
- 🇺🇸
University of California Davis, Sacramento, California, United States
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
- Conditions
- Acute Myelogenous LeukemiaAML
- Interventions
- First Posted Date
- 2014-11-10
- Last Posted Date
- 2022-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 94
- Registration Number
- NCT02287233
- Locations
- 🇺🇸
Univ Kansas Med Ctr /ID# 131175, Kansas City, Kansas, United States
🇺🇸Vanderbilt University Medical Center /ID# 131177, Nashville, Tennessee, United States
🇺🇸Weill Cornell Medical College /ID# 131170, New York, New York, United States
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- Conditions
- Newly Diagnosed AML With FLT3 Activating Mutations
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02283177
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.